Istituto di Biostrutture e Bioimmagini-CNR, via Mezzocannone 16, 80134 Naples, Italy
Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, I-50019 Sesto Fiorentino Firenze, Italy
Universit degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, I-50019 Sesto Fiorentino Firenze, Italy
References: Friedman, J.M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J.O., Wyatt, H.R., Reed, G.W., Peters, J.C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Ioannides-Demos, L.L., Proietto, J., Tonkin, A.M., McNeil, J.J., Safety of drug therapies used for weight loss and treatment of obesity (2006) Drug Saf, 29, pp. 277-302
Campfield, L.A., Smith, F.J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
Van Gaal, L., Mertens, I., Effects of obesity on cardiovascular systems and blood pressure control, digestive disease and cancer (1998) Clinical obesity, pp. 205-225. , Kopelman P. Ed, Oxford, Blackwell
Avenell, A., Broom, J., Brown, T.J., Poobalan, A., Aucott, L., Stearns, S.C., Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement (2004) Health Technol Assess, 8, pp. 1-182
Halford, J.C.G., Pharmacotherapy for obesity (2006) Appetite, 46, pp. 6-10
Chaput, J.P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur J Clin Pharmacol, 62, pp. 793-803
Cheetham, S.C., Jackson, H.C., Vickers, S.P., Dickinson, K., Jones, R.B., Heal, D.J., Novel targets for the treatment of obesity: A review of progress (2004) Drug discovery today therapeutic strategies, 1, pp. 227-235
Gadde, K.M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr. Drug Targets Cardiovasc. Haematol. Disord, 5, pp. 549-556
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J., RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patientA: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775
Bays, H., Dujovne, C., Pharmacotherapy of obesity: Currently marketed and upcoming agents (2002) Am J Cardiovasc Drugs, 2, pp. 245-253
Menelly, W., Goa, K.L., Drugs 1998, , Sibutramine. A review of its contribution to\ the management of obesity
Fujioka, K., Seaton, T.B., Rowe, E., Jelinek, C.A., Raskin, P., Lebovitz, H.E., Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus (2000) Diabetes Obes Metab, 2, pp. 175-187
Sidhaye, A., Cheskin, L.J., Pharmacologic treatment of obesity (2006) Adv Psychosom Med, 27, pp. 42-52
Davidson, M.H., Hauptman, J., DiGirolamo, M., Foreyt, J.P., Halsted, C.H., Heber, D., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P.A., Elbein, S.C., Hirsch, I.B., Kelley, D., McGill, J., Taylor, T., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Rössner, S., Sjöström, L., Noack, R., Meinders, A.E., Noseda, G., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes Res, 8, pp. 49-61
Rucker, D., Padwall, R., LI, S.K., Curioni, C., Lau, D.C.W., Long term pharmacotherapy for obesity and overweight: Updated meta-analiysis (2007) BMJ, , in press
Bray, G.A., Ryan, D.H., Drug treatment of the overweight patient (2007) Gastroenterology, 132, pp. 2239-2252
Padwal, R.S., Majumdar, S.R., Drug treatments for obesity: Orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Bays, H.E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes Res, 12, pp. 1197-1211
Supuran CT. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nature Reviews Drug Discovery 2008
7: In pressSupuran, C.T., Scozzafava, A., Casisni, A., Carbonic anhydrase inhibitors (2003) Med Res Rev, 23, pp. 146-189
Supuran, C.T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity (2003) Expert Opin the Pat, 13, pp. 1545-1550
Tripp, B.C., Smith, K., Ferry, J.G., Carbonic anhydrase: New insights for an ancient enzyme (2001) J Biol Chem, 276, pp. 48615-48618
(2004) Carbonic anhydrase - Its inhibitors and activitors, pp. 1-363. , Supuran CT, Scozzafava A, Conway J. Eds, CRC Press, Boca Raton FL, USA
Dodgson, S.J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J Appl Physiol, 63, pp. 2134-2141
Dodgson, S.J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am J Physiol, 257, pp. E791-E796
Spencer, I.M., Hargreaves, I., Chegwidden, W.R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem Soc Trans, 16, pp. 973-974
Chegwidden, W.R., Spencer, I.M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp Biochem Physiol, 115 B, pp. 247-254
Chegwidden, W.R., Dodgson, S.J., Spencer, I.M., The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals. In Chegwidden WR, Edwards Y (2000) The Carbonic Anhydrases, pp. 343-363. , Carter N. Eds, New Horizons. Birkhäuser Verlag, Basel
Lynch, C.J., Fox, H., Hazen, S.A., Stanley, B.A., Dodgson, S.J., Lanoue, K.F., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem J, 310, pp. 197-202
Hazen, S.A., Waheed, A., Sly, W.S., Lanoue, K.F., Lynch, C.J., Differentiation-dependent expression of CA V and the role or carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P.V., The structure and mechanism of action of pyruvate carboxylase (1995) Int J Biochem Cell Biol, 27, pp. 231-249
Alldred, J.B., Reilly, K.E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog Lipid Res, 35, pp. 371-385
Forster, R.E., Dodgson, S.J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The Carbonic Anhydrases, pp. 263-280. , Chegwidden WR, Edwards Y, Carter N. Eds, New horizons. Birkhäuser Verlag, Basel
Parkkila, S., An overview of the distribution and function of carbonic anhydrase isozymes in mammals (2000) The Carbonic Anhydrases, pp. 79-94. , Chegwidden WR, Edwards Y, Carter N. Eds, New Horizons. Birkhäuser Verlag, Basel
Parkkila, S., Parkkila, A.K., Kivelä, J., Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology (2004) Carbonic anhydrase, its inhibitors and activators, pp. 283-301. , Supuran, C.T, Scozzafava, A, Conway, J. Eds, CRC Press, Boca Raton
Edmonds, H.L., Jiang, Y.D., Zhang, P.Y., Shank, R.P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. PL127-PL131
Stringer, J.L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Sabers, A., Gram, L., Newer anticonvulsants: Comparative review of drug interactions and adverse effects (2000) Drugs, 60, pp. 23-33
Bourgeois, B.F.D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J Child Neurol, 15, pp. S27-S30
Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P., Perucca, E., Summary of the Fifth Eilat Conference Progress report on new antiepileptic drugs, , Epilepsy Res 2001
Gordon, A., Price, L.H., Mood stabilization and weight loss with topiramate (1999) Am J Psychiatry, 156, pp. 968-969
Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Richard, D., Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats (2000) Obes Res, 8, pp. 656-663
Casini, A., Antel, J., Abbate, F., Scozzafava, A., David, S., Waldeck, H., Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV (2003) Bioorg Med Chem Lett, 13, pp. 841-845
Vitale, R.M., Pedone, C., Amodeo, P., Antel, J., Wurl, M., Scozzafava, A., Carbonic anhydrase inhibitors: Molecular modelling study for the interaction of zonisamide and topiramate with isozyme va (2007) Bioorg Med Chem, 15, pp. 4152-4158
Zareba, G., Zonisamide: Review of its use in epilepsy therapy (2005) Drug Today (Barc), 41, pp. 589-597
Kim, C.S., Zonisamide effective for weight loss in women (2003) J Fam Pract, 52, pp. 600-601
Jennings, J.E., Zonisamide use in obesity and eating disorders. PCT. Int (2003), Appl, WO 2003092682 18 ppDe Simone, G., Di Fiore, A., Menchise, V., Pedone, C., Antel, J., Casini, A., Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies (2005) Bioorg Med Chem Lett, 15, pp. 2315-2320
Masuda, Y., Karasawa, T., Inhibitory effect of zonisamide on human carbonic anhydrase in vitro (1993) Arzneimittelforschung, 43, pp. 416-418
Gadde, K.M., Franciscy, D.M., Wagner 2nd, H.R., Krishnan, K.R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
Friedman, J. M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J. O., Wyatt, H. R., Reed, G. W., Peters, J. C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Campfield, L. A., Smith, F. J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
Halford, J. C. G., Pharmacotherapy for obesity (2006) Appetite, 46, pp. 6-10
Chaput, J. P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur J Clin Pharmacol, 62, pp. 793-803
Cheetham, S. C., Jackson, H. C., Vickers, S. P., Dickinson, K., Jones, R. B., Heal, D. J., Novel targets for the treatment of obesity: A review of progress (2004) Drug discovery today therapeutic strategies, 1, pp. 227-235
Gadde, K. M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr. Drug Targets Cardiovasc. Haematol. Disord, 5, pp. 549-556
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patientA: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
R ssner, S., Sj str m, L., Noack, R., Meinders, A. E., Noseda, G., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes Res, 8, pp. 49-61
Bray, G. A., Ryan, D. H., Drug treatment of the overweight patient (2007) Gastroenterology, 132, pp. 2239-2252
Padwal, R. S., Majumdar, S. R., Drug treatments for obesity: Orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Bays, H. E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes Res, 12, pp. 1197-1211
Supuran, C. T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity (2003) Expert Opin the Pat, 13, pp. 1545-1550
Tripp, B. C., Smith, K., Ferry, J. G., Carbonic anhydrase: New insights for an ancient enzyme (2001) J Biol Chem, 276, pp. 48615-48618
Dodgson, S. J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J Appl Physiol, 63, pp. 2134-2141
Dodgson, S. J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am J Physiol, 257, pp. E791-E796
Spencer, I. M., Hargreaves, I., Chegwidden, W. R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem Soc Trans, 16, pp. 973-974
Chegwidden, W. R., Spencer, I. M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp Biochem Physiol, 115 B, pp. 247-254
Lynch, C. J., Fox, H., Hazen, S. A., Stanley, B. A., Dodgson, S. J., Lanoue, K. F., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem J, 310, pp. 197-202
Hazen, S. A., Waheed, A., Sly, W. S., Lanoue, K. F., Lynch, C. J., Differentiation-dependent expression of CA V and the role or carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P. V., The structure and mechanism of action of pyruvate carboxylase (1995) Int J Biochem Cell Biol, 27, pp. 231-249
Alldred, J. B., Reilly, K. E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog Lipid Res, 35, pp. 371-385
Forster, R. E., Dodgson, S. J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The Carbonic Anhydrases, pp. 263-280. , Chegwidden WR, Edwards Y, Carter N. Eds, New horizons. Birkh user Verlag, Basel
Shank, R. P., Gardocki, J. F., Vaught, J. L., Davis, C. B., Schupsky, J. J., Raffa, R. B., Topiramate: Preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H. L., Jiang, Y. D., Zhang, P. Y., Shank, R. P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. PL127-PL131
Stringer, J. L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Bourgeois, B. F. D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J Child Neurol, 15, pp. S27-S30
Vitale, R. M., Pedone, C., Amodeo, P., Antel, J., Wurl, M., Scozzafava, A., Carbonic anhydrase inhibitors: Molecular modelling study for the interaction of zonisamide and topiramate with isozyme va (2007) Bioorg Med Chem, 15, pp. 4152-4158
Kim, C. S., Zonisamide effective for weight loss in women (2003) J Fam Pract, 52, pp. 600-601
Jennings, J. E., Zonisamide use in obesity and eating disorders. PCT. Int (2003), Appl, WO 2003092682 18 ppDe Simone, G., Di Fiore, A., Menchise, V., Pedone, C., Antel, J., Casini, A., Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies (2005) Bioorg Med Chem Lett, 15, pp. 2315-2320
Gadde, K. M., Franciscy, D. M., Wagner 2nd, H. R., Krishnan, K. R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs?